Hester Biosciences Ltd (BOM:524669)

Q3 2026 Hester Biosciences Ltd Earnings Call Transcript

Jan 30, 2026 / 08:30 AM GMT

Release Date Price: ₹1482.8 (+3.19%)

Transcript

Key Points

Positve

Hester Biosciences Ltd (BOM:524669) reported a 12% revenue growth in Q3, with profitability improving by 140% year-on-year due to a favorable product mix and cost discipline.
The poultry healthcare division showed strong performance, growing 32% in Q3 and 17% over nine months, supported by deeper market penetration and stronger distribution coverage.
The company achieved a regulatory milestone by receiving marketing and manufacturing licenses for the H9N2 avian influenza vaccine, enhancing its poultry vaccine portfolio.
Hester Biosciences Ltd (BOM:524669) capitalized its fill-finish facility, effectively doubling product capacity, which is expected to support future growth.
The company is focusing on reducing dependence on tender-driven revenues and expanding its presence in commercial and export markets, aiming for a more balanced and resilient business model.

Negative

The animal healthcare division, including the ruminant and pet health segment, recorded a 38% decline in Q3 due to delays in government-led immunization programs.
Revenue for the nine-month period was down by 5%, indicating challenges in maintaining consistent growth across all segments.
The ruminant business was impacted by seasonal factors, including lower incidence of clinical cases and higher feed costs, affecting purchasing behavior.
In Africa, Q3 performance was affected by timing delays in institutional order execution and higher operating costs, despite positive performance over nine months.
The pet care segment remains in its early stages, contributing less than 5% to the animal healthcare revenue, indicating limited impact on overall financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HEST.NS - Hester Biosciences Ltd
Q3 2026 Hester Biosciences Ltd Earnings Call
Jan 30, 2026 / 08:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Hester Biosciences Q3 and 9 months FY26 earnings conference call hosted by ICICI Securities Limited. As a reminder, all participants' line will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing, then 0 on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Nisha Shetty from ICICI Securities Limited.

Thank you and over to you.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.